Regeneron is a fully integrated biopharmaceutical company that discovers, develops, manufactures, and commercializes pharmaceutical products for the treatment of serious medical conditions.

Regeneron was founded in 1988 with the conviction that strong science could lead to the development of new medicines that could help people with serious illnesses. Today we are on the road to realizing this vision. The Company currently has one marketed product and eight product candidates in clinical development in a variety of indications.

• ARCALYST^® (rilonacept) Injection for Subcutaneous Use is available for prescription in the United States for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS) in adults and children 12 and older.
  
  
• Three product candidates are in Phase 3 clinical development, created from our proprietary Trap technology:
  
  
  • Rilonacept, an inhibitor of interleukin-1 (IL-1), which is being developed for the prevention of gout in patients initiating uric acid-lowering therapy.
    
    
  • VEGF Trap-Eye, which is being developed in eye diseases using intraocular delivery in collaboration with Bayer HealthCare LLC
    
    
  • Aflibercept (VEGF Trap), which is being developed in oncology and evaluated in a variety of cancer types, in collaboration with the sanofi-aventis Group
• Earlier-stage clinical programs are evaluating product candidates that were developed using our proprietary technologies for making fully human monoclonal antibodies. All five antibodies are being developed in collaboration with sanofi-aventis, and include:
  
  
  • REGN88, an antibody to the Interleukin-6 receptor (IL-6R), which is being developed in rheumatoid arthritis
    
    
  • REGN475, an antibody to Nerve Growth Factor (NGF), which is being developed for the treatment of pain
    
    
  • REGN727, an antibody to a protein, Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9), associated with the regulation of low-density lipoprotein (LDL) "bad" cholesterol
    
    
  • REGN421, an antibody to Delta-like ligand-4 (Dll4), which is being developed in oncology
    
    
  • REGN668, an antibody to Interleukin-4 receptor (IL-4R) that is being evaluated in allergic and immune conditions

The Regeneron preclinical research programs are in the areas of oncology and angiogenesis, ophthalmology, metabolic and related diseases, muscle diseases and disorders, inflammation and immune diseases, bone and cartilage, pain, and cardiovascular diseases.

ARCALYST and all of our product candidates were discovered and developed by Regeneron - a testament to the company's investment in scientific excellence.

Our research laboratories and corporate offices are located in Tarrytown, New York, while our industrial operations (manufacturing and related facilities) are in Rensselaer, New York.

June 2010